Oncopeptides AB (OSTO:ONCO) EV-to-Revenue : 10.86 (As of May. 25, 2025)

View and export this data going back to 2017. Start your Free Trial

What is Oncopeptides AB EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Oncopeptides AB's enterprise value is kr432.85 Mil. Oncopeptides AB's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 was kr39.84 Mil. Therefore, Oncopeptides AB's EV-to-Revenue for today is 10.86.

The historical rank and industry rank for Oncopeptides AB's EV-to-Revenue or its related term are showing as below:

OSTO:ONCO' s EV-to-Revenue Range Over the Past 10 Years
Min: -108.85 Med: 10.54 Max: 512.82
Current: 10.86

During the past 11 years, the highest EV-to-Revenue of Oncopeptides AB was 512.82. The lowest was -108.85. And the median was 10.54.

OSTO:ONCO's EV-to-Revenue is ranked worse than
59.2% of 995 companies
in the Biotechnology industry
Industry Median: 7.17 vs OSTO:ONCO: 10.86

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2025-05-25), Oncopeptides AB's stock price is kr1.996. Oncopeptides AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 was kr0.20. Therefore, Oncopeptides AB's PS Ratio for today is 9.83.

Oncopeptides AB EV-to-Revenue Historical Data

The historical data trend for Oncopeptides AB's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncopeptides AB EV-to-Revenue Chart

Oncopeptides AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

EV-to-Revenue

Get a 7-Day Free Trial

2.39

91.28

18.47

9.22

Oncopeptides AB Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
EV-to-Revenue	Get a 7-Day Free Trial															15.23	16.41	11.83	9.22	8.12

Competitive Comparison of Oncopeptides AB's EV-to-Revenue

For the Biotechnology subindustry, Oncopeptides AB's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oncopeptides AB's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncopeptides AB's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Oncopeptides AB's EV-to-Revenue falls into.

Save Embed

;

Save Embed

;

Oncopeptides AB EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Oncopeptides AB's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	432.845	/	39.843
	=	10.86

Oncopeptides AB's current Enterprise Value is kr432.85 Mil.
Oncopeptides AB's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was kr39.84 Mil.

Oncopeptides AB (OSTO:ONCO) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Oncopeptides AB's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	1.996	/	0.203
	=	9.83

Oncopeptides AB's share price for today is kr1.996.
Oncopeptides AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.20.

Oncopeptides AB EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Oncopeptides AB's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Oncopeptides AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncopeptides AB (OSTO:ONCO) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

0RN4:UK OND:Germany

Address

Vastra Tradgardsgatan 15, Stockholm, SWE, SE-111 53

Website

https://www.oncopeptides.com

Oncopeptides AB is a biotech company focused on the research, development, and commercialization of therapies for difficult-to-treat hematological diseases. The company uses its proprietary Peptide Drug Conjugate (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. It has focused on the development of the product candidate Melflufen (Pepaxti), a peptide-conjugated alkylator, belonging to a new class of drugs called Peptidase Enhanced Compounds. Melflufen is intended as an effective treatment for hematological cancers and in particular multiple myeloma.